Navigation Links
Experimental Antidepressants Offer Faster Relief
Date:9/5/2007

But initial research involved only rats; clinical trials involving people are next step

WEDNESDAY, Sept. 5 (HealthDay News) -- A new class of antidepressants dramatically cut the time needed to take effect when they were tested on rats, a study found.

The study authors, from McGill University in Montreal, Canada, said they hope the finding will spur research into the family of drugs, raising the prospect of faster-acting antidepressants.

But, as always with studies involving animals, the findings must first be confirmed in humans.

"The only way we'll know is when a clinical trial is done" involving humans, said Gerald Frye, Joseph H. Shelton professor of neuropharmacology and neurotoxicology at the Texas A&M Health Science Center College of Medicine's department of neuroscience and experimental therapeutics. "It looks promising from an animal standpoint, and the animal systems they're using are pretty good, but this can only predict. There's no guarantee."

Frye was not involved with the study, which is published in the Sept. 6 issue of the journal Neuron.

Antidepressant drugs known as selective serotonin reuptake inhibitors (SSRIs), which include Prozac and Celexa, are widely prescribed but can take up to six weeks to take effect, and they don't work for everyone. Many patients have to try several different drugs before achieving success, and only about 65 percent of people end up responding to a drug, according to an accompanying editorial in the journal.

That time lag can be critical for someone suffering from depression. "During that time, there is a risk of suicide," Frye said. "Anything you can do to get a faster response" is desirable, he added.

SSRIs work by enhancing the action of the neurotransmitter serotonin in the brain.

The new study looked at a new class of drugs known as serotonin4 (5-HT4) receptor agonists, which have a more specific effect.

"SSRIs interfere with the serotonin system and increase naturally transmitted serotonin to help the system readjust itself," Frye explained. "The new drugs act only on one receptor. They're more selective."

For the study, the researchers tested two serotonin receptor agonist compounds, called RS 67333 and prucalopride, in rats, comparing the drugs against the action of Celexa. Using different measures of depression, the researchers found that the two new drugs acted four to seven times faster and also seemed more powerful.

In one test, the researchers found that one of the serotonin receptor agonists took effect after only three days and completely erased the depressive symptoms after one week.

For instance, mild stress has been shown to reduce consumption of sugar water by rodents -- a behavior alleviated by weeks of SSRI treatment. But the McGill researchers found that one of the serotonin receptor agonists produced effects within three days and seemed to removed the depressive symptoms within a week.

The new drugs, however, may have side effects. "There are potential side effects, and that's where the rub could be with clinical trials," Frye said.

More information

For more on depression, visit the U.S. National Institute of Mental Health.



SOURCES: Gerald Frye, Ph.D., Joseph H. Shelton Professor of Neuropharmacology and Neurotoxicology, Department of Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine; Sept. 6, 2007, Neuron


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental SARS Vaccine
4. Experimental vaccine for shingles is effective
5. Experimental Blood Test May Spot Heart Attack Risk, Study Says
6. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
7. TMC 114 and 125 experimental drugs to be tested on four HIV patients
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... containerization, today announced an exhibitor sponsorship at MobileIron Live! 2017 in ... new technologies for an immersive, educational approach to helping organizations maximize the benefits ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, ... today announced it has completed a round of funding to accelerate its growth ... partners. Black Granite Capital is a growth equity firm focused on investments in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader ... in a new class of photodynamic cosmetics (PDC). , Allumera® is the first ... outward signs of aging, and minimize the appearance of pores – all with ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: